Another global, phase Ib trial in previous anti-PD1 or anti-PD-L1 treated, patients with NRAS-mutant advanced melanoma aims to compare belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab (NCT04835805). The gene discussed is CD274; the disease is melanoma.